A carregar...
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
BACKGROUND: Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non‐small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patien...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7262941/ https://ncbi.nlm.nih.gov/pubmed/32291896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13429 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|